Tag: SCAI 2025
FAVOR III identifies major risk factors of cardiovascular events after PCI
New findings from the FAVOR III China trial demonstrate that kidney function, followed by body m...
“Urgent need” to move away from lead in mitigating cath lab radiation exposure
With an increasing focus on the harmful impact of radiation exposure, as well as the risk of ort...
SCAI names Srihari S Naidu as president
The Society for Cardiovascular Angiography & Interventions (SCAI) has announced its new lead...
SCAI 2025: Early TAVI “should be preferred to clinical surveillance in all age groups”
Analysis from the EARLY TAVR trial, presented at the 2025 Society for Cardiovascular Angiography &am...
SCAI 2025: Stenting “improves long-term survival” for patients undergoing CTO PCI
In patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI), stent...
SCAI 2025: SAPT after TAVI should be considered “standard of care”
Single antiplatelet therapy (SAPT) after transcatheter aortic valve implantation (TAVI) is associate...
